Mer­ck to with­draw dan­gling ac­cel­er­at­ed ap­proval for Keytru­da in third-line stom­ach can­cer

4 years ago
R&D
FDA+

Years af­ter bank­rupt­cy, Den­dreon adds a con­tract man­u­fac­tur­ing wing

4 years ago
Outsourcing
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: In­dia starts man­u­fac­tur­ing of No­vavax vac­cine — re­port; US ships spare shots to ...

4 years ago
Coronavirus
Manufacturing

WuXi will add 500 jobs at Delaware man­u­fac­tur­ing cam­pus as it looks to bol­ster its CD­MO arm

4 years ago
Outsourcing
Manufacturing

New to the par­ty, No­var­tis seeks to plunge in­to mR­NA

4 years ago
R&D

Kin­tara of­fers peek at mid-stage da­ta in re­lapsed glioblas­toma pa­tients; Jazz wins quick ap­proval for pe­di­atric ...

4 years ago
News Briefing

Mer­ck ex­tends deal to see what else NG­M's dis­cov­ery en­gine can come up with

4 years ago
Deals

Vet­er­an amy­loid cham­pi­on helps Alzheimer's start­up grab $160M in IPO as in­vestors charge back in to a once fad­ed ...

4 years ago
Financing
R&D

Roche mulling quick fil­ing for a tar­nished Alzheimer’s drug as con­tro­ver­sial Aduhelm OK elec­tri­fies the field — ...

4 years ago
R&D
FDA+

Roche reach­es out once again for the bud­get ax with plans to chop up to 400 de­vel­op­ment jobs in R&D

4 years ago
R&D
Pharma

Catal­ent bags a Ger­man stem cell de­vel­op­er to build its next-gen ther­a­peu­tics wing

4 years ago
R&D
Outsourcing

A vi­ral vec­tor play­er is ex­pand­ing its foot­print in Basque Coun­try amid height­ened de­mand

4 years ago
Outsourcing
Manufacturing

Fu­ji­film out­lays whop­ping $850M for its Diosynth CM­DO wing, look­ing to rapid­ly scale cell cul­ture pro­duc­tion

4 years ago
Outsourcing
Manufacturing

Hori­zon takes the leap in­to man­u­fac­tur­ing, buy­ing out an Irish plant with around 40 em­ploy­ees in tow

4 years ago
Outsourcing
Manufacturing

Nestlé is bet­ting $525M on a bid to pi­o­neer world's first mi­cro­bio­me drug

4 years ago
Deals

Covid-19 roundup: Cure­Vac push­es ahead for vac­cine au­tho­riza­tion de­spite fail­ing to hit 50% ef­fi­ca­cy thresh­old

4 years ago
Coronavirus

Pfiz­er bets on Spero can­di­date, wad­ing deep­er along­side GSK and Roche in­to aban­doned an­tibi­ot­ic mar­ket

4 years ago
R&D

An­oth­er re­pur­posed drug bites the dust in Covid-19 as An­gion bails on or­gan dam­age drug ef­fort

4 years ago
R&D
Coronavirus

From base­ment lab to Wall Street: Ab­sci looks to bring its 'pro­tein print­ing' plat­form pub­lic

4 years ago
Financing

Ac­tivist El­liott be­gins its long-await­ed at­tack on CEO Em­ma Walm­s­ley and a Glax­o­SmithK­line that has 'lost its way'

4 years ago
Financing
Deals

Apel­lis, Beam team up to test base edit­ing against the broad field of com­ple­ment dis­or­ders

4 years ago
Deals
Cell/Gene Tx

3 gene ther­a­py com­pa­nies se­cure VC mon­ey; No­valis clos­es near­ly $30 mil­lion fund

4 years ago
News Briefing

For­mer Viela CEO Bing Yao finds his next gig — bring­ing Chi­nese R&D in­no­va­tion state­side

4 years ago
Startups
China

ICER finds Bio­gen’s new ex­or­bi­tant­ly priced Alzheimer’s drug doesn’t match even an op­ti­mistic view of po­ten­tial ...

4 years ago
Pharma
First page Previous page 672673674675676677678 Next page Last page
A service from the Financial Times